Company intelligence / Profile preview

Femtobiomed

Seongnam-si, Gyeonggi-do, South Koreafemtobiomed.com ↗

Ownership: Private
Development stage: Commercial

Overview

Femtobiomed develops advanced non-viral gene delivery and next-generation electroporation systems for use in cell and gene therapy manufacturing. Their main product, CELLSHOT, is a cargo-free intracellular delivery platform designed to improve the efficiency of engineering cells for therapeutic applications. The company’s technologies are positioned as enabling tools/platforms rather than direct clinical-stage therapeutics.

Modalities: DeviceCell therapy (enabling technology)Gene therapy (enabling technology)
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Femtobiomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Femtobiomed.

Explore the full profile